Dapsone for thrombocytopenic purpura related to human immunodeficiency virus infection

Durand, J.-M.; Lefevre, P.; Hovette, P; Issifi, Soumana; Mongin, M

doi:10.1016/s0002-9343(05)80054-3

Cited by 26 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results also show that dapsone is less effective in patients with profound thrombocytopenia and, as reported by Durand et al [4,6], that discontinuation leads to relapse of PTAI. In our opinion, dapsone should not thus be proposed as an alternative to splenectomy in young AITP patients.…”

Section: Discussionsupporting

confidence: 89%

“…Dapsone was recently described as effective treatment for AITP in a small number of HIV-infected [6] and HIV-free patients [4,5]. The results of this larger series confirm that this is the case, since platelet counts increased significantly in half of our patients ( 13/27 pts).…”

Section: Discussionsupporting

confidence: 83%

“…Splenectomy is effective but traumatic, and drugs known to increase the platelet count in such patients (immunosuppressive agents, danazol, intravenous IgG) are not always or only transiently effective, toxic and/or expensive. Treatment with dapsone has been reported in preliminary studies to effective in five elderly AITP patients [4], in a patient with AITP and systemic lupus erythematosus [ 5 ] , and in 6/11 patients with HIV-related AITP [6]. We report our experience in 27 patients.…”

Section: Introductionmentioning

confidence: 91%

See 2 more Smart Citations

Dapsone for autoimmune thrombocytopenic purpura

1993

View full text Add to dashboard Cite

Twenty-one human immunodeficiency virus (HIV)-free and six HIV-infected adults with autoimmune thrombocytopenic purpura (AITP) were treated with dapsone (100 mg/day). A response was observed in 13 patients (median platelet count before 25 x 10(9)/L, range 3-49; after 109 x 10(9)/L, range 69-241). Thrombocytopenia recurred in four of the responders in whom dapsone was discontinued. No response was observed in 12 patients. Dapsone had to be withdrawn after two weeks of treatment in the remaining two patients and after six to eight weeks in three other patients due to intolerance. No serious hematological complications were observed. These results confirm that dapsone is a safe, inexpensive, and effective treatment of AITP.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Dapsone for autoimmune thrombocytopenic purpura

1993

View full text Add to dashboard Cite

show abstract

“…Thereafter, the success of this therapeutic option for treating refractory thrombocytopenia in various conditions, such as ITP, systemic lupus erythematosus, and primary antiphospholipid syndrome, was reported in a string of case reports [10,[12][13][14]. In some of these reports, it was successfully used in children, HIV-positive patients, the elderly, and pregnant women [9,[15][16][17][18].…”

Section: Dapsone For Persistent and Chronic Itp In Adultsmentioning

confidence: 99%

“…The successful use of dapsone for treating thrombocytopenia secondary to systemic lupus erythematosus and HIV infection was first reported~25 years ago. Since then, several authors have assessed its efficacy in treating refractory chronic ITP, with good results [8][9][10][11]. Dapsone is a cheaper alternative with fewer side effects.…”

Section: Introductionmentioning

confidence: 99%

Dapsone for primary immune thrombocytopenia in adults and children: an evidence‐based review

Rodrigo

Gooneratne

2013

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

To cite this article: Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost 2013; 11: 1946-53. Summary. Primary immune thrombocytopenia is a potentially life-threatening condition. Approximately two-thirds of adult patients do not have a sustained response to steroids (first-line therapy). For these patients, a number of other treatment options exist, such as rituximab, splenectomy, immunosuppressants, and thrombopoietin receptor agonists, but they are costly and have side effects. Dapsone is an inexpensive drug with a well-established safety profile. Unfortunately, this treatment option has not been explored adequately. This review is aimed at analyzing the currently available evidence for the use of dapsone as second-line or third-line therapy in primary immune thrombocytopenia.

show abstract